Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Research & Development (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Research & Development for 8 consecutive years, with $3.6 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 62.38% to $3.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.2 million through Dec 2025, down 25.46% year-over-year, with the annual reading at $27.2 million for FY2025, 34.92% down from the prior year.
  • Research & Development for Q4 2025 was $3.6 million at Outlook Therapeutics, down from $6.0 million in the prior quarter.
  • The five-year high for Research & Development was $9.7 million in Q4 2024, with the low at $3.6 million in Q4 2025.